Jayant S. Vaidya

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

Jayant S. Vaidya, Frederik Wenz, Max Bulsara et al. · The Lancet · 2013 · 822 citations · Full text

Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial

Jayant S. Vaidya, David Joseph, Jeffrey Tobias et al. · The Lancet · 2010 · 756 citations · Full text

Surgical Oncology, Breast Oncology, Radiation Therapy +7

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial

Jayant S. Vaidya, Max Bulsara, Michael Baum et al. · BMJ · 2020 · 279 citations · Full text

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Targeted Intraoperative Radiotherapy Impairs the Stimulation of Breast Cancer Cell Proliferation and Invasion Caused by Surgical Wounding

Barbara Belletti, Jayant S. Vaidya, Sara D’Andrea et al. · Clinical Cancer Research · 2008 · 230 citations